Abstract: The present invention relates to novel heterocyclic compounds. The invention is also directed to compounds which are modulators of the metabotropic glutamate receptors (mGluR), preferably of the metabotropic glutamate receptor subtype 7 (“mGluR7”). The present invention also relates to pharmaceutical composition comprising such compounds and their use for the treatment or prevention of disorders associated with glutamate dysfunction or in which metabotropic glutamate receptor, preferably mGluR7 subtype of metabotropic glutamate receptors, is involved.

Abstract: Process for the preparation of vorasidenib using N,N?-bis[(2R)-1,1,1-trifluoropropan-2-yl]triimidodicarbonic diamide hydrochloride

Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Disclosed are an oxadiazole compound having a structure of formula (I), a pharmaceutical composition comprising same, and the use thereof as an HDAC6 inhibitor.

Abstract: The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions.

Abstract: Disclosed is a trifluoromethyl-substituted sulfonamide BCL-2-selective inhibitor, in particular disclosed are a compound of formula I, a stereoisomer or a pharmaceutically acceptable salt thereof, a preparation method therefore, and a pharmaceutical composition thereof. Also disclosed are the uses of said compound and of a pharmaceutical composition comprising same for treating anti-apoptotic BCL-2-related diseases, such as cancer.

Abstract: The present invention belongs to the field of pharmaceuticals, and particularly relates to a tricyclic compound, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite or prodrug thereof, a method for preparing same, a pharmaceutical composition comprising same, and uses thereof.

Abstract: Disclosed is a novel meta-polyhedral oligomeric silsesquioxane (meta-POSS) compound as a modified polyhedral oligomeric silsesquioxane, which is a polysiloxane-based compound, a preparation method thereof, and a composition containing the meta-POSS compound prepared by the preparation method. The novel meta-POSS compound is characterized by including a structural unit of —Si—O—R2-O—Si—. R2 is —(CH2)2—, —(CH2)3—, —(CH2)4—, —(CH2)3—, —(CH2)6—, —(CH2)8—, —(CH2)10—, or —(CH2)12—.

Abstract: Monoorgano tin trialkoxide compounds having chemical formula R?SnX3 and containing less than about 5 mol % R?2SnX2 are described. R? is an optionally substituted organic substituent having about 1 to about 20 carbon atoms and each X is independently ORf, wherein Rf is a fluorinated organic substituent having about 1 to about 20 carbon atoms. Methods for synthesizing and purifying these compounds are also provided. The monoorgano tin compounds may be used for the formation of high-resolution EUV lithography patterning precursors and are attractive due to their high purity and minimal concentration of diorgano tin impurities.

Abstract: Organometallic complexes are described which are useful as pre-polymerization catalysts which may form part of olefin polymerization catalyst systems. The catalyst systems find use in the polymerization of ethylene, optionally with one or more C3-12 alpha-olefin comonomers. The organometallic complexes are broadly represented by formula I: wherein L is a bridging group containing a contiguous chain of atoms connecting P with Cy, wherein the contiguous chain contains 2 or 3 atoms and wherein Cy is a cyclopentadienyl-type ligand. The olefin polymerization catalyst system is effective at polymerizing ethylene with alpha-olefins in a solution phase polymerization process at high temperatures and produces ethylene copolymers with high molecular weight and high degrees of alpha-olefin incorporation. Pre-metallation compounds, metallation processes and synthetic methods to make the organometallic complexes as well as polymerization processes are also described.

Abstract: A composite material for an organic solar cell including a polyoxometalate (POM) cluster and a self-assembled monolayer (SAM) of a carbazole-based compound. The method for preparing the composite material and the use of such a composite material are also addressed.

Abstract: Disclosed are messenger RNA molecules and related compositions incorporating a 4?-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4?-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies.

Abstract: Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v), and wherein L1, L2, L3, X1, X2, Y, Rz4, Rz5, Rz6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.

Abstract: The present invention relates to a method for reducing lipopolysaccharides activity and/or lipopolysaccharides in a collagen-containing and/or collagen-derived product and products obtained by the method. The method comprises the steps of providing a collagen-containing and/or collagen-derived product comprising lipopolysaccharides, contacting the collagen-containing and/or collagen-derived product comprising lipopolysaccharides with a polyglycol ether of a fatty alcohol to provide a mixture and recovering a collagen-containing and/or collagen-derived product.

Abstract: Provided are a hybrid protein comprising a CFH functional unit and a DAF functional unit. an encoding nucleic acid thereof, and a method and use thereof for treating related diseases or disorders of a complement system.

Abstract: This disclosure relates to, inter alia, cells expressing both a chimeric antigen receptor (CAR) and membrane bound IL-12 and the use of these cells to target and treat cancers (e.g., solid tumors and cancers expressing CD19, CD22, BCMA, PSCA, HER2, TAG-72, and PSCA). The disclosure also relates to cells expressing a membrane bound IL-12.

Abstract: An anti-cleavage mutant of CD16 for enhancing cell function is provided. Specifically, the CD16 mutant has an amino acid residue mutation at the following sites corresponding to a wild-type CD16: insertion of one or more proline between V196 and S197 sites and/or between S197 and T198 sites of CD16-F176V. The CD16 mutant of the present invention can resist the cleavage of ADAM17, and can enhance the ADCC capability of NK92 cell line expressing same.

Abstract: A fatigue-resistant load-bearing steel for a wind turbine main shaft, and a manufacturing method and a use thereof are provided. The manufacturing method includes: step S1, smelting: smelting a raw steel into a molten iron, followed by impurity removal and deoxidation, and adjusting contents of respective components to obtain a casting molten steel; step S2, continuous casting: crystallizing the casting molten steel with an electric pulse, followed by solidification to obtain a continuous casting billet; step S3, rolling: subjecting the continuous casting billet to rough rolling and finish rolling sequentially to obtain a finish-rolled billet; and step S4, post-rolling treatment: slowly cooling and then air-cooling the finish-rolled billet to obtain the fatigue-resistant load-bearing steel.

Abstract: The present disclosure includes a differential heat treatment method for a forming roller including an outer circumferential surface heat treatment step for heating the outer circumferential surfaces of roller units. The method may additionally include a first natural cooling step for naturally cooling until the surface temperature reaches 100-150° C., an inner circumferential surface heat treatment step for heating the inner circumferential surfaces of the roller units. The method may additionally include a second cooling step for naturally cooling until the roller units reach a room temperature state after the inner circumferential heat treatment. Further, the method may include an inspection and release step for inspecting the hardness of the outer circumferential surface and the inner circumferential surface after the second cooling and releasing when the hardness is within an error range.